A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection

New England Journal of Medicine

Volumn 344, Issue 3, 2001, Pages 159-167

  Lopez De Bernaldo Quiros, Juan C ^a   Miro, Jose M ^b   Peña, Jose M ^c   Podzamczer, Daniel ^d   Alberdi, Juan C ^e   Martínez, Esteban ^b   Cosin, Jaime ^a   Claramonte, Xavier ^b   Gonzalez, Juan ^c   Domingo, Pere ^f   Casado, Jose L ^g   Ribera, Esteban ^h  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Residencia Sanitaria La Paz   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MULTIVARIATE ANALYSIS; PNEUMONIA, PNEUMOCYSTIS; RNA, VIRAL; STATISTICS, NONPARAMETRIC; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0035905903     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200101183440301     Document Type: Article

References (42)

1. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1
2. Opportunistic diseases reported in AIDS patients: Frequencies, associations, and trends
3. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus
4. Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia: A randomized, placebo-controlled study
5. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS
6. Intermittent co-trimoxazole prophylaxis against Pneumocystis carinii pneumonia
7. Intermittent trimethoprimsulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV
8. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection
9. The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease
10. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients
11. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
12. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both
13. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
14. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
15. Changing patterns of mortality across Europe in patients infected with HIV-1
16. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
17. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs
18. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
19. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
20. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
21. Discontinuation of Pneumocystis carinii pneumonia after start of highly active antiretroviral therapy in HIV-1 infection
22. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy
23. Discontinuation of PCP prophylaxis is safe in HIV-infected patients with immunological recovery with HAART: Preliminary results of an open, randomized and multicentric clinical trial (GESIDA 04/98)
24. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)
25. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group protocol 021
26. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
27. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy
28. Response to immunization with recall antigens and neoantigens after 48 weeks of HAART
29. Immune reconstitution in HIV infection
30. Immune reconstitution under highly active antiretroviral therapy
31. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: The changes in opportunistic prophylaxis study
32. Pneumocystis carinii pneumonia
33. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy
34. In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii
35. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons
36. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
37. Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4+ lymphocytes
38. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
39. Opportunistic infections occurring during highly active antiretroviral treatment
40. Does Pneumocystis carinii prophylaxis still need to be lifelong?
41. Decline in CMV and other opportunistic diseases with combination antiretroviral therapy
42. HIV plasma RNA, an independent predictor of opportunistic infections in HIV-infected persons